Navigation Links
Duska Therapeutics Applies for Phase 3 Special Protocol Assessment
Date:11/20/2008

LA JOLLA, Calif., Nov. 20 /PRNewswire-FirstCall/ -- Duska Therapeutics, Inc., (OTC Bulletin Board: DSKA), announced today that it has submitted its pivotal Phase 3 ATPace clinical trial protocol for review under a Special Protocol Assessment (SPA) procedure with the U.S. Food and Drug Administration (FDA).

Subject to securing an agreement with the FDA, Duska intends to initiate a single, prospective, double-blind, placebo-controlled and randomized Phase 3 clinical trial with its lead product ATPace. This trial is aimed at demonstrating clinical safety and efficacy of ATPace in treating paroxysmal supraventricular tachycardia, or PSVT, in emergency room patients. Upon successful completion of the trial, Duska intends to file a New Drug Application under section 505(b)(2).

The SPA is a process that provides for an official FDA evaluation of Phase 3 clinical study protocols. Once the SPA is agreed to by both the FDA and the trial sponsor, the SPA provides the sponsor with a binding written agreement that the design and analysis of the studies are adequate to support a license application submission if the study is performed according to the SPA and if the results are successful. The SPA agreement may only be changed by the sponsor company or the FDA by a written agreement, or if the FDA becomes aware of a substantial scientific issue essential to product efficacy or safety.

PSVT, one of the most common cardiac arrhythmias, is a rapid, regular heart rate originating in the atria. There are approximately 570,000 persons with PSVT in the United States alone, with an estimated 89,000 new cases diagnosed each year. Patients with PSVT may report palpitations, pounding in the chest, chest pressure or pain, weakness, shortness of breath, or dizziness. The heart rate in PSVT can range from 150-250 beats per minute.

ATPace, a stable liquid formulation of adenosine 5'-triphosphate (ATP) for intraven
'/>"/>

SOURCE Duska Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Duska Therapeutics Licenses Portfolio of Heart Failure Drugs From Duke and Johns Hopkins
2. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
3. Cell Therapeutics Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
4. Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
5. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
6. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
7. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
8. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
9. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
10. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
11. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Sept. 17, 2014 Women everywhere know how ... not only uncomfortable, they,re often also embarrassing and have ... Feminine Health Support ( http://ph-defense.com ) is a new, ... an all-natural, homeopathic product. Odor, discharge, ... of vaginal infection. In many cases, the cause of ...
(Date:9/17/2014)... 2014  Aratana Therapeutics, Inc. (NASDAQ: ... licensing, developing and commercializing innovative biopharmaceutical products for ... public offering of 4,500,000 shares of its common stock at ... share. Aratana has granted the underwriters a 30-day ... shares of its common stock. Jefferies ...
(Date:9/17/2014)... , Sept. 17, 2014  Neuraltus Pharmaceuticals, Inc. announced ... 2 clinical program of NP001 for the treatment of ... disease) are being highlighted today in an oral presentation ... Group , being held in Bloomington, Minnesota ... hoc  analysis, administration of a high dose of NP001 ...
Breaking Medicine Technology:New Product from Vireo Systems: pH-D Feminine Health Support 2Aratana Therapeutics, Inc. Announces Pricing of Public Offering 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3
... (ASH) Annual Meeting ... Publication Number: 840, ... thromboses (blood clots),and transfusion requirements in patients with a rare ... have,been expected to have less severe disease, according to data ...
... Mich., Dec. 10 CSG/SportsCoatings and,the National Wrestling ... the most proactive and proven method of controlling,bacteria, ... Nationally renowned for its Sports Antimicrobial System (R) ... on all types of,athletic surfaces and fabrics for ...
Cached Medicine Technology:PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 2PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 3PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 4PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 5PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 6PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 7PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity 8National Wrestling Coaches Association Teams Up With CSG/SportsCoatings(TM) 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 Final Cut Pro ... entitled ProBlue 5k from Pixel Film Studios. , “ProBlue 5k ... users video from good to epic,” said Christina Austin, CEO ... armature, ProBlue 5k is a definite game changer.” , ProBlue ... package for any filmmaker ! This footage compilation of ...
(Date:9/17/2014)... 2014 People who struggle to distinguish between ... http://www.perwickstrom.com and get the answer by reading Per ... out, is that a business plan and a business strategy ... commented Per Wickstrom. “The way I view it is that ... strategy which is part two.” , According to the ...
(Date:9/17/2014)... IL (PRWEB) September 17, 2014 The ... Pseudomonas aeruginosa infections allegedly caused by Non-Sterile Other-Sonic ... learn more about their options for legal recourse. Other-Sonic ... Drug Administration (FDA) in March 2012, after the product ... aeruginosa at William Beaumont Hospital in Royal Oak, Michigan ...
(Date:9/17/2014)... Dennis Thompson HealthDay Reporter ... in the womb to household chemicals known as phthalates ... Columbia University researchers reported in a new study. ... developing asthma between age 5 and 11 if their ... two phthalates (pronounced thal-ates), the researchers found. The two ...
(Date:9/17/2014)... FRISCO, Texas (PRWEB) September 17, 2014 ... (EV-D68) outbreak that is hospitalizing scores of infants, children ... Louisiana, says Dr. Kirk Mahon, medical director of Legacy ... , “There have been no reported cases of EV-D68 ... Oklahoma and Louisiana, that could change,” he said. “Implementing ...
Breaking Medicine News(10 mins):Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 2Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 3Health News:Prenatal Exposure to Chemicals in Plastics Linked to Asthma Risk in Kids 4Health News:Legacy ER & Urgent Care Warns North Texans about Dangers of Enterovirus D68 2
... 17 (HealthDay News) -- Among long-term breast cancer survivors, those ... much higher rates of death due to heart disease, new ... Jan. 25 issue of the Journal of the American ... such as that practiced until the mid-1980s, increased the long-term ...
... birth weight in First Nations (North American Indian) babies are ... that occur from 4 weeks to 1 year of age), ... Canadian Medical Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100837.pdf ... as a child being born above the 90th percentile relative ...
... By Steven Reinberg HealthDay Reporter , ... are taking common blood pressure medications called calcium channel ... blood pressure and possibly going into shock if they ... antibiotics, erythromycin and clarithromycin, if given to patients taking ...
... on the milk we drink, according to new research ... during a particularly poor UK summer and the following ... less beneficial fatty acids than in a more ,normal, ... organic milk could help overcome these problems. Organic ...
... HealthDay Reporter , SATURDAY, Jan. 15 (HealthDay News) -- ... the breathing tube that had been in place since she ... attack in Tucson that killed six people. The new ... the Associated Press . The breathing tube had been ...
... January 14, 2011The ongoing controversy about the appropriate ... be explored at the upcoming 19th Annual Congress ... DC. A provocative "Point-Counterpoint: The Mammography Controversy" will ... PhD, Visiting Professor of Radiology, Magee-Womens Hospital, University ...
Cached Medicine News:Health News:Breast Cancer Radiation Before 1984 Tied to Heart Disease 2Health News:High birth weight in First Nations babies linked to a higher risk of postneonatal death 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 2Health News:Some Antibiotics, Blood Pressure Meds a Bad Mix: Study 3Health News:Choosing organic milk could offset effects of climate change 2Health News:Choosing organic milk could offset effects of climate change 3Health News:Choosing organic milk could offset effects of climate change 4Health News:Rep. Giffords Has Surgery to Replace Breathing Tube 2Health News:Rep. Giffords Has Surgery to Replace Breathing Tube 3Health News:Mammography controversy to be explored at 19th Annual Congress on Women's Health 2
For the quantitative in vitro determination of Microalbumin in urine....
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with kaolin activator....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: